- Home
- ENIC vs GH Comparison
ENIC vs GH Comparison
Compare ENIC & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENIC
- GH
- Stock Information
- Founded
- ENIC 2016
- GH 2011
- Country
- ENIC Chile
- GH United States
- Employees
- ENIC N/A
- GH N/A
- Industry
- ENIC Electric Utilities: Central
- GH Medical Specialities
- Sector
- ENIC Utilities
- GH Health Care
- Exchange
- ENIC Nasdaq
- GH Nasdaq
- Market Cap
- ENIC 3.6B
- GH 3.0B
- IPO Year
- ENIC N/A
- GH 2018
- Fundamental
- Price
- ENIC $2.67
- GH $25.39
- Analyst Decision
- ENIC
- GH Strong Buy
- Analyst Count
- ENIC 0
- GH 17
- Target Price
- ENIC N/A
- GH $39.31
- AVG Volume (30 Days)
- ENIC 699.4K
- GH 2.6M
- Earning Date
- ENIC 10-31-2024
- GH 11-04-2024
- Dividend Yield
- ENIC 9.21%
- GH N/A
- EPS Growth
- ENIC N/A
- GH N/A
- EPS
- ENIC 0.01
- GH N/A
- Revenue
- ENIC $4,788,825,821.00
- GH $643,810,000.00
- Revenue This Year
- ENIC $18.54
- GH $27.01
- Revenue Next Year
- ENIC N/A
- GH $18.30
- P/E Ratio
- ENIC $4.37
- GH N/A
- Revenue Growth
- ENIC N/A
- GH 26.20
- 52 Week Low
- ENIC $2.51
- GH $15.81
- 52 Week High
- ENIC $3.53
- GH $37.04
- Technical
- Relative Strength Index (RSI)
- ENIC 47.35
- GH 44.39
- Support Level
- ENIC $2.59
- GH $23.07
- Resistance Level
- ENIC $2.73
- GH $27.13
- Average True Range (ATR)
- ENIC 0.08
- GH 1.29
- MACD
- ENIC 0.00
- GH 0.22
- Stochastic Oscillator
- ENIC 56.14
- GH 57.14
About ENIC Enel Chile S.A. (Each representing 50 shares of)
Enel Chile SA is an electricity utility company, which through its subsidiaries and affiliates is engaged in the generation, transmission and distribution of electricity businesses in Chile. It operates through two segments including Generation Business and Distribution and Network Business. The Generation Business Segment is comprised of a group of electricity companies that own electricity generating plants, whose energy is transmitted and distributed to end customers. The Distribution and Network Reportable Segment is comprised of a group of electricity companies operating under a public utility concession.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.